Last reviewed 2026-04-19 · How we verify

ALPIROPRIDE

Phase 2 active Small molecule

ALPIROPRIDE is a alpiropride drug. It is currently in Phase 2 development.

Alpiropride works by binding to dopamine receptors in the brain.

Alpiropride is a small molecule drug in the alpiropride class, originally developed by an unknown entity and currently owned by an unknown entity. Its target and approved indications are unknown, and it has not been approved by the FDA. Alpiropride has a half-life of 4.8 hours, but its bioavailability and commercial status are unknown. Further research is needed to determine its safety and efficacy. As a result, it is not commercially available.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ALPIROPRIDE
Drug class	alpiropride
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your brain is a city with many different streets and buildings. Dopamine is like a messenger that helps different parts of the city communicate with each other. Alpiropride is like a key that helps this messenger work more effectively, which can help treat certain conditions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ALPIROPRIDE CI brief — competitive landscape report
ALPIROPRIDE updates RSS · CI watch RSS

Frequently asked questions about ALPIROPRIDE

What is ALPIROPRIDE?

ALPIROPRIDE is a alpiropride drug.

How does ALPIROPRIDE work?

Alpiropride works by binding to dopamine receptors in the brain.

What drug class is ALPIROPRIDE in?

ALPIROPRIDE belongs to the alpiropride class. See all alpiropride drugs at /class/alpiropride.

What development phase is ALPIROPRIDE in?

ALPIROPRIDE is in Phase 2.

Drug class: All alpiropride drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing